T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CYS
1976
DELISTED
CYS Investments Inc.
CYS
| $463K | ﹤0.01% |
51,352
+1,293
| +3% | +$11.4K |
|
1977
Granite Construction
GVA
$5.41B
| $462K | ﹤0.01% |
12,850
| – | – |
|
1978
Integra LifeSciences
IART
$1.42B
| $461K | ﹤0.01% |
23,975
+4,893
| +26% | +$91.2K |
|
1979
MBIA
MBI
$262M
| $461K | ﹤0.01% |
41,750
-14,000
| -25% | -$172K |
|
1980
MKS Inc
MKSI
$20.7B
| $460K | ﹤0.01% |
14,713
| – | – |
|
|
HK
1981
DELISTED
Halcon Resources Corporation
HK
| $460K | ﹤0.01% |
366
-2,533
| -87% | -$2.53M |
|
1982
Primerica
PRI
$9.62B
| $459K | ﹤0.01% |
9,600
+3,600
| +60% | +$165K |
|
|
EMBJ
1983
Embraer S.A. ADS
EMBJ
$13.2B
| $455K | ﹤0.01% |
12,500
| – | – |
|
|
NUVA
1984
DELISTED
NuVasive, Inc.
NUVA
| $452K | ﹤0.01% |
12,700
| – | – |
|
|
OVTI
1985
DELISTED
OMNIVISION TECHNOLOGIES INC
OVTI
| $452K | ﹤0.01% |
20,552
+390
| +2% | +$7.94K |
|
1986
Universal Corp
UVV
$1.12B
| $451K | ﹤0.01% |
8,151
+1,200
| +17% | +$65.4K |
|
1987
LXP Industrial Trust
LXP
$3.58B
| $450K | ﹤0.01% |
8,170
| – | – |
|
|
NSR
1988
DELISTED
Neustar Inc
NSR
| $450K | ﹤0.01% |
17,300
+3,100
| +22% | +$84.2K |
|
|
CPE
1989
DELISTED
Callon Petroleum Company
CPE
| $448K | ﹤0.01% |
3,845
-1,260
| -25% | -$125K |
|
1990
Andersons Inc
ANDE
$2.21B
| $441K | ﹤0.01% |
8,550
| – | – |
|
|
LTC
1991
LTC Properties
LTC
$2.1B
| $439K | ﹤0.01% |
11,250
+2,700
| +32% | +$105K |
|
1992
Pearson
PSO
$9.78B
| $438K | ﹤0.01% |
22,100
+5,400
| +32% | +$101K |
|
1993
Strategy Inc
MSTR
$38.2B
| $437K | ﹤0.01% |
31,060
| – | – |
|
1994
SouthState Bank Corp
SSB
$10.8B
| $437K | ﹤0.01% |
7,159
+1,300
| +22% | +$77.1K |
|
1995
Vishay Intertechnology
VSH
$5.11B
| $437K | ﹤0.01% |
28,198
| – | – |
|
|
KERX
1996
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $437K | ﹤0.01% |
28,400
| – | – |
|
1997
Coeur Mining
CDE
$19B
| $436K | ﹤0.01% |
47,470
| – | – |
|
1998
Cal-Maine
CALM
$3.87B
| $431K | ﹤0.01% |
11,600
| – | – |
|
1999
Kaiser Aluminum
KALU
$2.99B
| $430K | ﹤0.01% |
5,900
| – | – |
|
|
IGTE
2000
DELISTED
IGATE CORPORATION
IGTE
| $429K | ﹤0.01% |
11,800
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.